(Q42726594)

English

Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin

scientific article published on 27 September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

1 reference

based on heuristic

inferred from title

esophageal squamous cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yota Yamamoto

1

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Hiromichi Yamai

2

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Junichi Seike

3

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Takahiro Yoshida

4

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Hirokazu Takechi

5

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Yoshihito Furukita

6

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Koichiro Kajiura

7

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Takuya Minato

8

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Yoshimi Bando

9

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Akira Tangoku

10

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

publication date

27 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Annals of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

757-765

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

https://scigraph.springernature.com/pub.10.1245/s10434-011-2071-y

0 references

Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Salvage oesophagectomy after local failure of definitive chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Salvage esophagectomy after high-dose chemoradiotherapy for esophageal squamous cell carcinoma.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Current perspectives on HER2 testing: a review of national testing guidelines

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Evaluation of prognostic factors of esophageal squamous cell carcinoma (stage II-III) after concurrent chemoradiotherapy using biopsy specimens

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Epidermal growth factor receptor is a possible predictor of sensitivity to chemoradiotherapy in the primary lesion of esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Repeat motifs of tau bind to the insides of microtubules in the absence of taxol

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

ErbB-3 predicts survival in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Relationship between proliferative activity of cancer cells and clinicopathological factors in patients with esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Predictive factors of the response to chemoradiotherapy in esophageal cancer

1 reference

https://api.crossref.org/works/10.1245%2FS10434-011-2071-Y

21 January 2018

Identifiers

10.1245/S10434-011-2071-Y

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42726594&oldid=1967979813"